Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
Dow Jones Industrial Average
) is trading up 42 points (+0.3%) at 13,600 as of Tuesday, Sep 25, 2012, 11:35 a.m. ET. During this time, 193.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 584.1 million. The NYSE advances/declines ratio sits at 1,793 issues advancing vs. 1,078 declining with 146 unchanged.
- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
The Dow component leading the way higher looks to be
), which is sporting a 32-cent gain (+1.3%) bringing the stock to $25.07. This single gain is lifting the Dow Jones Industrial Average by 2.42 points or roughly accounting for 5.8% of the Dow's overall gain. Volume for Pfizer currently sits at 15 million shares traded vs. an average daily trading volume of 31.5 million shares.
Pfizer has a market cap of $183.11 billion and is part of the
industry. Shares are up 13.3% year to date as of Monday's close. The stock's dividend yield sits at 3.6%.
Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 20.8, above the average drugs industry P/E ratio of 18.2 and above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Pfizer as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
- You can view the full Pfizer Ratings Report.
FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!
Free download now